• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.

作者信息

Page Evaren E, Kremer Hovinga Johanna A, Terrell Deirdra R, Vesely Sara K, George James N

机构信息

Department of Biostatistics and Epidemiology, College of Public Health and Hematology-Oncology Section, Department of Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK; and.

Department of Hematology and Central Hematology Laboratory, University Hospital of Bern, Department of Clinical Research, University of Bern, Bern, Switzerland.

出版信息

Blood. 2016 Jun 16;127(24):3092-4. doi: 10.1182/blood-2016-03-703827. Epub 2016 Apr 8.

DOI:10.1182/blood-2016-03-703827
PMID:27060171
Abstract
摘要

相似文献

1
Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.利妥昔单抗可降低血栓性血小板减少性紫癜患者的复发风险。
Blood. 2016 Jun 16;127(24):3092-4. doi: 10.1182/blood-2016-03-703827. Epub 2016 Apr 8.
2
Outcome of Thrombotic Thrombocytopenic Purpura Patients: A Single-Center Experience.血栓性血小板减少性紫癜患者的结局：单中心经验
Turk J Haematol. 2019 Aug 2;36(3):214-215. doi: 10.4274/tjh.galenos.2019.2019.0048. Epub 2019 Mar 25.
3
Management of thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜的管理
Transfus Clin Biol. 2017 Sep;24(3):148-153. doi: 10.1016/j.tracli.2017.05.015. Epub 2017 Jun 20.
4
Thrombotic Thrombocytopenic Purpura Treated with Rituximab Associated with Primary Sjögren's Syndrome and Primary Hypothyroidism.利妥昔单抗治疗血栓性血小板减少性紫癜合并原发性干燥综合征和原发性甲状腺功能减退症
Intern Med. 2020 Mar 1;59(5):715-719. doi: 10.2169/internalmedicine.3722-19. Epub 2019 Nov 8.
5
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.预防性利妥昔单抗可预防免疫介导性血栓性血小板减少性紫癜的长期复发。
Blood. 2018 Nov 15;132(20):2143-2153. doi: 10.1182/blood-2018-04-840090. Epub 2018 Sep 10.
6
Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment.免疫介导的血栓性血小板减少性紫癜的强化利妥昔单抗方案可避免对标准利妥昔单抗治疗无反应。
Br J Haematol. 2021 Jan;192(1):e21-e25. doi: 10.1111/bjh.17170. Epub 2020 Nov 20.
7
Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura.皮质类固醇和利妥昔单抗作为血栓性血小板减少性紫癜的辅助治疗。
Am J Hematol. 2012 May;87 Suppl 1:S88-91. doi: 10.1002/ajh.23126. Epub 2012 Mar 9.
8
Therapeutic plasma exchange in thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜的治疗性血浆置换
Presse Med. 2019 Nov;48(11 Pt 2):319-327. doi: 10.1016/j.lpm.2019.08.024. Epub 2019 Nov 20.
9
Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review.儿童获得性血栓性血小板减少性紫癜：利妥昔单抗预防复发。一份儿科报告及文献综述。
Haematologica. 2018 Mar;103(3):e138-e140. doi: 10.3324/haematol.2017.185363.
10
Obinutuzumab in two patients suffering from immune-mediated thrombotic thrombocytopenic purpura intolerant to rituximab.奥滨尤妥珠单抗治疗两名对利妥昔单抗不耐受的免疫介导性血栓性血小板减少性紫癜患者。
Am J Hematol. 2019 Oct;94(10):E259-E261. doi: 10.1002/ajh.25583. Epub 2019 Aug 9.

引用本文的文献

1
A Thrombocytopenic Thrombotic Purpura in a Patient With a Metastatic HER2+ Breast Cancer: Description of a Case Report.一名HER2阳性转移性乳腺癌患者并发血小板减少性血栓性紫癜：病例报告描述
Clin Case Rep. 2025 Apr 8;13(4):e70395. doi: 10.1002/ccr3.70395. eCollection 2025 Apr.
2
A Descriptive 5-Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021.美国免疫性血栓性血小板减少性紫癜患者的人口统计学和治疗方法的描述性5年分析：一项对2017年至2021年390例疾病发作的多中心研究
J Clin Apher. 2025 Apr;40(2):e70017. doi: 10.1002/jca.70017.
3
Very low doses of rituximab in autoimmune hemolytic anemia-an open-label, phase II pilot trial.
极低剂量利妥昔单抗治疗自身免疫性溶血性贫血——一项开放标签的II期试点试验
Front Med (Lausanne). 2024 Dec 20;11:1481333. doi: 10.3389/fmed.2024.1481333. eCollection 2024.
4
Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era.在利妥昔单抗时代接受治疗的一部分免疫介导性血栓性血小板减少性紫癜（TTP）黑人患者中，无复发生存期逐渐缩短。
Blood Adv. 2025 Jan 28;9(2):417-424. doi: 10.1182/bloodadvances.2024013313.
5
Immune Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, Therapy and Open Issues.免疫性血栓性血小板减少性紫癜：病理生理学、诊断、治疗及未解决的问题。
Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024060. doi: 10.4084/MJHID.2024.060. eCollection 2024.
6
Association of thrombotic microangiopathy with interferon therapy for hepatitis B: a case report.乙型肝炎干扰素治疗相关血栓性微血管病：病例报告。
J Med Case Rep. 2024 Jul 5;18(1):321. doi: 10.1186/s13256-024-04635-8.
7
Clinical Features and Risk Factors of Relapse and Mortality in Thrombotic Thrombocytopenic Purpura Patients: A Seven-Year Experience.血栓性血小板减少性紫癜患者复发和死亡的临床特征及危险因素：七年经验
Int J Hematol Oncol Stem Cell Res. 2023 Jul 1;17(3):156-166. doi: 10.18502/ijhoscr.v17i3.13305.
8
Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura.利妥昔单抗治疗免疫介导的血栓性血小板减少性紫癜
Blood Transfus. 2023 Sep;21(5):369-374. doi: 10.2450/BloodTransfus.503. Epub 2023 Mar 17.
9
Immune thrombotic thrombocytopenic purpura: Spotlight on long-term outcomes and survivorship.免疫性血栓性血小板减少性紫癜：聚焦长期结局与生存情况。
Front Med (Lausanne). 2023 Feb 28;10:1137019. doi: 10.3389/fmed.2023.1137019. eCollection 2023.
10
Refractory Thrombotic Thrombocytopenic Purpura to Therapeutic Plasma Exchange.对治疗性血浆置换难治的血栓性血小板减少性紫癜
Cureus. 2022 Sep 25;14(9):e29562. doi: 10.7759/cureus.29562. eCollection 2022 Sep.